The 35 year quest for a vaccine that confers protective efficacy against congenital infection with human cytomegalovirus (HCMV) remains unmet. Complexities in HCMV natural history, incompletely defined correlates of immune protection and financial and logistical factors in designing sufficiently powered clinical trials all contribute to the absence of a licensed HCMV vaccine(s). There is now increased recognition from studies in both humans and rhesus macaques (RM) that (1) the mechanism of HCMV and rhesus CMV (RhCMV) entry into cells, such as endothelial and epithelial cells, is distinct from the mechanism of fibroblast entry, and (2) seroimmune individuals develop neutralizing antibodies against the viral proteins mediating epithelial/endothelial cell tropism. Studies with HCMV show that the UL128, 131A, 130 proteins together form a complex with gH and gL that is essential for epithelial/endothelial cell tropism via an endocytic pathway, and the absence of any one of these proteins greatly restricts HCMV infection to gB-mediated entry into cells, such as fibroblasts. The preponderance of evidence from natural history and tissue culture studies evidence indicates that vaccine strategies will need to block both the endocytic (UL128 complex) and fibroblast (gB) entry pathways to establish a sufficient level of protective immunity to reduce or prevent congenital infection. The data with HCMV and our progress in both expressing a secreted form of RhCMV UL128 from rMVA as a single subunit and characterizing the role of the UL128 complex in RhCMV natural history lead to the hypothesis that vaccine strategies targeting the UL128 complex will show enhanced restriction of virus shedding in bodily fluids. Based on this hypothesis, vaccination of RhCMV-naove RM with the UL128 complex will have a significantly reduced frequency and titer of systemic infectious virus, resulting in reduced levels of shed virus. This hypothesis will be rigorously tested in our primate model of HCMV persistence and pathogenesis through the following Aims. (1) Construction and characterization of plasmid expression and MVA vectors for the UL128 complex. (2) Optimization of vaccination in macaques with expression vectors constructed in Aim 1, and characterization of peripheral and mucosal antibody responses to the UL128 complex in RhCMV-infected macaques. (3) Immunization of RhCMV-negative RM by the optimized prime/boost regimen from Aim 2 followed by either a subcutaneous or mucosal route of RhCMV challenge capable of both fibroblast and endocytic entry.
This proposal will show in a primate RhCMV model that faithfully recapitulates human infection and expresses the monkey equivalent of the HCMV UL128 complex that a protective vaccine augmented with RhCMV UL128 complex antigens will significantly limit the capacity of challenge virus to disseminate. These studies should lead to an optimal prophylactic HCMV clinical strategy that can lead to clinically relevant reductions in the potential for both vertical and horizontal transmission of HCMV.
|Wussow, Felix; Chiuppesi, Flavia; Meng, Zhuo et al. (2018) Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex. J Virol Methods 251:30-37|
|Wussow, Felix; Chiuppesi, Flavia; Contreras, Heidi et al. (2017) Neutralization of Human Cytomegalovirus Entry into Fibroblasts and Epithelial Cells. Vaccines (Basel) 5:|
|Fan, Qihua; Nelson, Cody S; Bialas, Kristy M et al. (2017) Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission. Clin Vaccine Immunol 24:|
|Nelson, Cody S; Cruz, Diana Vera; Tran, Dollnovan et al. (2017) Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys. JCI Insight 2:|
|Yue, Yujuan; Kaur, Amitinder; Lilja, Anders et al. (2016) The susceptibility of primary cultured rhesus macaque kidney epithelial cells to rhesus cytomegalovirus strains. J Gen Virol 97:1426-1438|
|Cavicchioli, Laura; Zanetti, Rossella; Ferraresso, Serena et al. (2015) Expression of recipient cytomegalovirus in immunosuppressed and xenotransplanted Macaca fascicularis may be related to more severe gastrointestinal lesions. Xenotransplantation 22:135-43|
|Davis, Zachary B; Cooley, Sarah A; Cichocki, Frank et al. (2015) Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transpla Biol Blood Marrow Transplant 21:1653-62|
|Oxford, Kristie L; Dela Pena-Ponce, Myra Grace A; Jensen, Kara et al. (2015) The interplay between immune maturation, age, chronic viral infection and environment. Immun Ageing 12:3|
|Gibson, Laura; Barysauskas, Constance M; McManus, Margaret et al. (2015) Reduced frequencies of polyfunctional CMV-specific T cell responses in infants with congenital CMV infection. J Clin Immunol 35:289-301|
|Chiuppesi, Flavia; Wussow, Felix; Johnson, Erica et al. (2015) Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection. J Virol 89:11884-98|
Showing the most recent 10 out of 28 publications